Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment: a pilot study

Gauthier S, Reisberg B, Zaudig M et al (2006) Mild cognitive impairment. Lancet 367:1262–1270 Mucke L (2009) Neuroscience: Alzheimer’s disease. Nature 461:895–897 Petersen RC (2007) Mild cognitive impairment: current research and clinical implications. Semin Neurol 27:22–31 Johnson KA, Jones K, Holman BL et al (1998) Preclinical prediction of Alzheimer’s disease using SPECT. Neurology 50:1563–1571 McKelvey R, Bergman H, Stern J et al (1999) Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci 26:23–28 Petersen RC, Doody R, Kurz A et al (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992 Morris JC, Storandt M, Miller JP et al (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58:397–405 Grundman M, Petersen RC, Ferris SH et al (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61:59–66 Kantarci K, Weigand SD, Petersen RC et al (2007) Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 28:1330–1339 Chao LL (2010) Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. Neurobiol Aging 31:368–377 Rosen Y, Lenki RE (2007) Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics 4:330–345 Kizu O, Yamada K, Ito H et al (2004) Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy. Neuroradiology 46:277–281 Jansen JF, Backes WH, Nicolay K et al (2006) 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 240:318–332 Knight-Scott J, Haley AP, Rossmiller SR et al (2003) Molality as a unit of measure for expressing 1H MRS brain metabolite concentrations in vivo. Magn Reson Imaging 21:787–797 Doelken MT, Mennecke A, Stadlbauer A et al (2009) Multi-voxel magnetic resonance spectroscopy of cerebral metabolites in healthy adults at 3 Tesla. Acad Radiol 16:1493–1501 Provencher SW (2001) Automatic quantitation of localized in vivo 1H-spectra with LCModel. NMR Biomed 14:260–264 Waldman AD, Rai GS (2003) The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer’s disease and vascular dementia: a proton magnetic resonance spectroscopy study. Neuroradiology 45:507–512 Ackl N, Ising M, Schreiber YA et al (2005) Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 384:23–28 Catani M, Cherubini A, Howard R et al (2001) 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12:2315–2317 Schuff N, Meyerhoff DJ, Mueller S et al (2006) N-Acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv Exp Med Biol 576:241–262 Siger M, Schuff N, Zhu X et al (2009) Regional myo-inositol concentration in mild cognitive impairment: using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 231:57–62 Dixon RM, Bradley KM, Budge MM et al (2002) Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease. Brain 125:2332–2341 Jessen F, Block W, Traber F et al (2000) Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55:684–688 Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment clinical characterization and outcome. Arch Neurol 56:303–308 Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412–2414 Folstein MF, Folstein SE, McHugh PR (1975) Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198 Barberger-Gateau P, Commenges D, Gagnon M et al (1992) Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 40:1129–1134 Chang CC, Kramer JH, Lin KN et al (2010) Validating the Chinese version of the verbal learning test for screening Alzheimer’s disease. J Int Neuropsychol Soc 16:244–251 Reisberg B, Ferris SH, de Leon MJ et al (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139:1136–1139 Larson DB, Lyons JS, Bareta JC et al (1989) The construct validity of the ischemic score of Hachinski for the detection of dementias. J Neuropsychiatry Clin Neurosci 1:181–187 Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 4:695–699 Ebel A, Maudsley AA (2005) Detection and correction of frequency instabilities for volumetric 1H echo-planar spectroscopic imaging. Magn Reson Med 53:465–469 Minoshima S, Giordani B, Berent S et al (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94 Huang CR, Wahlund LO, Svensson L et al (2002) Cingulate cortex hypoperfusion predicts Alzheimer’s disease in mild cognitive impairment. BMC Neurol 2:9. doi:10.1186/1471-2377-2-9 Chételat G, Desgranges B, de la Sayette V et al (2003) Mild cognitive impairment: can FDG-PET predicts who is to rapidly convert to Alzheimer’s disease? Neurology 60:1374–1377 Drzezga A, Lautenschlager N, Siebner H et al (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104–1113 Moffett JR, Ross B, Arun P et al (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81:89–131 Harada M, Miyoshi H, Otsuka H et al (2001) Multivariate analysis of regional metabolic differences in normal ageing on localised quantitative proton MR spectroscopy. Neuroradiology 43:448–452 Modrego PJ, Fayed N, Pina MA (2005) Conversion from mild cognitive impairment to probable Alzheimer’s disease predicted by brain magnetic resonance spectroscopy. J Psychiatry 162:667–675 Rami L, Gómez-Ansón B, Bosch B et al (2007) Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer’s disease. Dement Geriatr Cogn Disord 24:274–279 Scahill RI, Schott JM, Stevens JM et al (2002) Mapping the evolution of regional atrophyin Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 99:4703–4707 Fayed N, Dávila J, Oliveros A et al (2008) Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol 15:1089–1098 Olson BL, Holshouser BA, Britt W et al (2008) Longitudinal metabolic and cognitive changes in mild cognitive impairment patients. Alzheimer Dis Assoc Disord 22:269–277 Metastasio A, Rinaldi P, Tarducci R et al (2006) Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 27:926–932 Kantarci K, Petersen RC, Boeve BF et al (2004) 1H MR spectroscopy in common dementias. Neurology 63:1393–1398 Watanabe T, Shiino A, Akiguchi I (2010) Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer’s disease and healthy aging. Dement Geriatr Cogn Disord 30:71–77 Martínez-Bisbal MC, Arana E, Martí-Bonmatí L et al (2006) Cognitive impairment: classification by proton magnetic resonance spectroscopy and the contributions of conventional magnetic resonance imaging. Radiologia 48:301–307 Selden NR, Gitelman DR, Salamon-Murayama N et al (1998) Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121:2249–2257 Chantal S, Braun CM, Bouchard RW et al (2004) Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 1003:26–35 Kantarci K, Weigand SD, Petersen RC et al (2006) Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 28:1330–1339 Tiehuis A, van der Meer F, Mali W et al (2010) MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance. Neuroradiology 52:155–161 Dickerson BC (2010) Advances in quantitative magnetic resonance imaging-based biomarkers for Alzheimer disease. Alzheimers Res Ther 2:21 Jahng GH, Xu S, Weiner MW, et al (2011) DTI studies in patients with Alzheimer’s disease, mild cognitive impairment, or normal cognition with evaluation of the intrinsic background gradients. Neuroradiology doi:10.1007/s00234-011-0845-3